One‐year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study
Alimentary Pharmacology & Therapeutics2017Vol. 46(3), pp. 310–321
Citations Over TimeTop 1% of 2017 papers
Aurélien Amiot, Mélanie Serrero, Laurent Peyrin‐Biroulet, Jérôme Filippi, Benjamin Pariente, Xavier Roblin, Anthony Buisson, Carmen Stefănescu, Caroline Trang-Poisson, Romain Altwegg, Philippe Marteau, Thibaut Vaysse, Anne Bourrier, Stéphane Nancey, David Laharie, Matthieu Allez, Guillaume Savoye, J. Moreau, Lucine Vuitton, S Viennot, Alexandre Aubourg, Anne-Laure Pelletier, Guillaume Bouguen, Véred Abitbol, Charlotte Gagnière, Yoram Bouhnik, the OBSERV‐IBD study group and the GETAID
Abstract
Vedolizumab is able to maintain steroid-free clinical remission in up to one-third of patients with UC and CD at week 54 with a reasonable safety profile. A significant number of patients experienced loss of response during the first year of treatment, particularly in patients with CD.
Related Papers
- → Infliximab in patients with severe steroid-refractory ulcerative colitis: Indian experience(2013)10 cited
- → Vedolizumab for the treatment of ulcerative colitis(2015)2 cited
- → Vedolizumab for induction and maintenance of remission in Crohn’s disease(2020)1 cited
- → Predictors of the efficacy of infliximab in patients with ulcerative colitis(2022)